Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 4/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.48 |
| ▸ | MERTK | Q12866 | 5/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3757377 | 0.98 | ULK1 (0.51) | ULK1PDK1ULK2NPY5RMERTK | |
| SCHEMBL3767353 | 0.96 | ULK1 (0.47) | ULK1PDK1ULK2NPY5RMERTK | |
| SCHEMBL3767946 | 0.87 | ULK1 (0.40) | ULK1PDK1ULK2NPY5RSOS1 | |
| SCHEMBL3767239 | 0.87 | NTRK1 (0.40) | ULK1PDK1ULK2NPY5RSOS1 | |
| SCHEMBL3769388 | 0.86 | NTRK1 (0.40) | ULK1PDK1ULK2 | |
| SCHEMBL3772000 | 0.85 | ULK1 (0.37) | ULK1PDK1ULK2NPY5RSOS1 | |
| SCHEMBL13054460 | 0.84 | ULK1 (0.69) | ULK1PDK1ULK2NPY5RMERTK | |
| SCHEMBL3769795 | 0.84 | AURKA (0.35) | ULK1PDK1ULK2SOS1AURKA | |
| SCHEMBL3762734 | 0.84 | ULK1 (0.38) | ULK1PDK1ULK2NPY5RSOS1 | |
| SCHEMBL3757445 | 0.83 | AURKA (0.47) | ULK1PDK1ULK2NPY5RSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-20040167121-A1 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167121-A1 | Indazolinone compositions useful as kinase inhibitors | LCK, CDK2, CILK1 | ULK1 575/4885PDK1 426/4885ULK2 396/4885 |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | LCK, CDK2, MKNK2 | ULK1 585/4885PDK1 422/4885ULK2 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.